From the archive1 min read
GBT launches ACCEL grants program to improve access to care for people with Sickle cell disease
Global Blood Therapeutics, Inc. (GBT) today announced the launch of the Access to Excellent Care for Sickle Cell Patients Pilot Program (ACCEL) to provide grant funding to support…
Business
About this article
- Published
- Last updated
oneSCDvoice
Global Blood Therapeutics, Inc. (GBT) today announced the launch of the Access to Excellent Care for Sickle Cell Patients Pilot Program (ACCEL) to provide grant funding to support novel projects aimed at improving access to high-quality healthcare for sickle cell patients in the United States.
GBT will fund as many as three proposals up to $50,000 each to accelerate the development of promising programs with the potential over time to deliver high-quality healthcare to people living with sickle cell disease (SCD).
“Studies show that healthcare delivery to people living with SCD is typically suboptimal. For example, in the United States, fewer than 10 percent of Medicaid and Medicare patients living with SCD see a hematologist at least once per year and approximately 20 percent of SCD patients receive most of their care in the emergency room,” said Jung Choi, who oversees patient advocacy and government affairs at GBT.